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Background: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts
(ESGICH) Consensus Document on the safety of targeted and biological therapies.
Aims: To review, from an Infectious Diseases perspective, the safety proﬁle of agents targeting CD19,
CD20 and CD52 and to suggest preventive recommendations.
Sources: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic
family.
Content: Although CD19-targeted agents (blinatumomab or inebilizumab) are not associated with an
increased risk of infection, they may cause IgG hypogammaglobulinaemia and neutropenia. The
requirement for prolonged intravenous infusion of blinatumomab may increase the risk of catheter-
associated bloodstream infections. Infection remains the most common non-haematological adverse
effect of anti-CD20 monoclonal antibodies, including severe respiratory tract infection, hepatitis B virus
(HBV) reactivation and varicella-zoster virus infection. Screening for chronic or resolved HBV infection is
recommended for patients receiving anti-CD20 monoclonal antibodies. Antiviral prophylaxis should be
offered for 12e18 months to hepatitis B surface antigen (HBsAg)-positive and HBsAg-negative/anti-
hepatitis B core antibody (HBc)-positive patients. Anti-Pneumocystis prophylaxis should be considered
in patients receiving concomitant chemotherapy, particularly steroids. Alemtuzumab (anti-CD52) in-
creases the risk of infections, in particular among leukaemia and solid organ transplant patients. These
populations beneﬁt from anti-Pneumocystis prophylaxis, prevention strategies for cytomegalovirus
infection, and screening for HBV, hepatitis C virus and tuberculosis. Antiviral prophylaxis for at least
6e12 months should be provided for HBsAg-positive patients.
Implications: As there are limited clinical data for many of the reviewed agents, special attention must be
given to promptly detect and report emerging infectious complications. M. Mikulska, Clin Microbiol
Infect 2018;24:S71
© 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.ectious Diseases, University of Genoa and Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132 Genoa, Italy.
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The present review paper is part of a larger effort launched by
the ESCMID (European Society of Clinical Microbiology and Infec-
tious Diseases) Study Group for Infections in Compromised Hosts
(ESGICH) and is aimed at analysing, from an Infectious Diseases
perspective, the safety proﬁle of biological and targeted therapies.
By means of a set of unrestricted computer-based MEDLINE (Na-
tional Library of Medicine, Bethesda, MD) searches based on the
MeSH terms appropriate for each agent or therapeutic family, we
identiﬁed literature pertaining to the participants. In addition,
package information and boxed warning alerts from regulatory
agencies (European Medicines Agency (EMA) and US Food and
Drug Administration (FDA)) were reviewed. Methodological details
are provided in the Introduction section of the present Supplement
issue [1]. For each agent (or class of agents), a common outline is
offered: (a) summary of mechanism of action, approved indications
and most common off-label uses; (b) theoretically expected impact
on the host's susceptibility to infection; (c) available evidence
emerging from the clinical use of that agent (i.e. randomized clin-
ical trials (RCTs), post-marketing studies, case series and single case
reports); and (d) suggested preventive and risk minimization
strategies. The present section is focused on the risk of infection
entailed by the use of monoclonal antibodies and antibody con-
structs targeting CD19, CD20 and CD52. The effects of chimeric
antigen receptor-modiﬁed T-cell therapy are beyond the scope of
this review. Agents targeted at other lymphoid cell surface antigens
(such as CD22, CD30, CD33, CD38, SLAMF7 or CCR4) and also used
in patients with haematological malignancies are covered in a
separate section of the document.
In the last two decades there has been an increasing interest in
developing monoclonal antibodies targeting different surface pro-
teins on lymphoid cells, mainly clusters of differentiation (CDs), for
the treatment of leukaemia and lymphoma. Althoughmost of these
newer drugs are used in combination with traditional chemother-
apeutic agents, they can also be prescribed as salvage or mainte-
nance monotherapy in selected cases. Additionally, some agents
(e.g. anti-CD20 or, more recently, anti-CD52 antibodies) are also
used in patients with autoimmune or immune-mediated condi-
tions, such as haemolytic anaemia, rheumatoid arthritis or multiple
sclerosis. For these indications they are usually used as mono-
therapy, and the cumulative dosage is usually lower than in hae-
matological malignancies.
The development status, therapeutic indications and potential
impact on the infectious risk of the reviewed agents are summa-
rized in Table 1. The available data on infectious complications
extracted from studies that included a control group are outlined in
Table 2. Characteristics of different anti-CD20 agents are shown in
Table 3. Finally, the suggested strategies for the prevention of
infection in patients treated with these agents are depicted in
Table 4.
CD19-directed agents: blinatumomab, inebilizumab and
combotox
Mechanism of action, approved indications and off-label uses
Blinatumomab (Blincyto®; Amgen, Thousand Oaks, CA, USA) is a
bispeciﬁc T-cell engager antibody construct designed to direct CD3-
expressing cytotoxic T cells to CD19-expressing B cells (Fig. 1) [2]. It
is approved in monotherapy by the FDA and the EMA for the
treatment of Philadelphia chromosome-negative relapsed or re-
fractory B-cell precursor acute lymphoblastic leukaemia (ALL). In
July 2017, blinatumomab was also approved by the FDA for Phila-
delphia chromosome-positive forms of the disease. A single cycle oftreatment consists of 4 weeks of continuous intravenous infusion
followed by a 2-week treatment-free interval, and a treatment
course consists of up to a total of ﬁve cycles (Table 1).
Inebilizumab (previously known as MEDI-551, MedImmune;
AstraZeneca, Cambridge, UK) is a humanized, afucosylated IgG1 k
monoclonal antibody that depletes CD19-expressing B cells
by means of antibody-dependent cell-mediated cytotoxicity.
Currently, this agent is in phase 3 studies for neuromyelitis optica,
a condition for which inebilizumab received in 2017 the status of
orphan drug from the EMA, and in earlier clinical testing phases for
chronic lymphocytic leukaemia (CLL), B-cell lymphoma, multiple
sclerosis, systemic scleroderma and multiple myeloma.
Combotox is a 1:1 mixture of two immunotoxins (HD37-dgRTA
and RFB4-dgRTA) obtained from coupling IgG1 monoclonal anti-
bodies targeted against CD19 and CD22 and a deglycosylated ricin A
chain (dgRTA, previously called dgA). CD19 is present on virtually
every malignant lymphoblast in patients with B-lineage ALL,
whereas the CD22 epitope is expressed on about 80% of the blast
population. Therefore, B-cell ALL and B-cell lymphoma are themain
therapeutic targets of combotox [3]. The dosage of combotox is still
to be standardized, and repeated cycles and escalation are
permitted in the absence of grade 3e4 toxicity or development of
speciﬁc antibodies [3].
Chimeric antigen receptor T cells have been also developed for
the treatment of ALL and other CD19-positive malignancies [4], but
their performance and safety are beyond the scope of this docu-
ment. Infectious complications associated with their use have been
recently reviewed [5].
Expected impact on the infection risk
The expression of CD19, which is almost exclusively restricted to
B cells, commences during early development stages of the cell
such as pro-B, pre-B and other immature cells, germinal centre,
naive and memory B cells, as well as in the majority of plasma cells
located in secondary lymphoid organs (such as spleen and tonsils).
All peripheral blood plasma cells and more than 50% of plasma cells
in bone marrow also express CD19 on their surface. Compared with
CD20, it is expressed at earlier development stages of B lympho-
cytes. Of note, CD19 is also present in the majority of B precursor
ALL blasts, hence its main indication.
CD19-targeted agents deplete normal B cells with the conse-
quent reduction in IgG levels. In a phase 3 RCT the presence of IgG
hypogammaglobulinaemia (HGG) occurred in 6% of patients in the
blinatumomab arm compared with 0.9% of those treated with
conventional chemotherapy [6]. The rate of neutropenia with bli-
natumomab was lower than with chemotherapy (38% versus 58%,
respectively) [6]. The length of HGG is difﬁcult to establish andmay
depend on the number of doses of blinatumomab. In a follow-up
report on six individuals with ALL from a phase 2 study with bli-
natumomab, only one exhibited normal serum IgG levels at
approximately 2 years from the initiation of treatment, whereas
none of them recovered IgA levels, even though half of them had
normal IgA serum levels at the initiation of therapy [7]. Since CD19,
but not CD20, is expressed on plasmablasts, CD19-targeted agents
are expected to induce a more profound decrease in serum
immunoglobulin levels than CD20-targeted agents [7]. Finally,
B-cell-dependent activation of T cells may be also affected by CD19-
targeted agents, as reported with anti-CD20 monoclonal
antibodies.
Available clinical data
Trials performed within the clinical development programme
for blinatumomab found no signiﬁcant differences in the incidence
Table 1
Description of the main agents targeting surface antigens on lymphoid cells
Agent Mechanism of action Status of development
(year of approval)
Approved indications Off-label or
experimental uses
Use as single
agent
Use as
ﬁrst-line
treatment
Cellular expression Type of immunity
impairment
Blinatumomab Bispeciﬁc CD19-directed
CD3þ T-cell engager
Approved, EMA (2015), FDA
(2014)
Ph-negative and Ph-
positive relapsed or
refractory B-cell precursor
ALL
DLBCL Yes No B cells (including
earlier stages),
follicular dendritic
cells
B cells, HGG, impaired
B-cell-dependent T-cell
activation
Inebilizumab
(previously MEDI-551)
Anti-CD19 monoclonal
antibody
Phase 2 and 3 studies in
NMO; phase 2 in CLL, SS,
B-cell lymphoma and MS;
phase 1 in MM
NA NA Yes No
Combotox Immunotoxins targeting
CD22 and CD19
Phase 2 studies in ALL
ongoing
NA NA Yes No See CD19 and CD 22
agents
See CD19 and CD22
agents
Rituximab Anti-CD20 monoclonal
antibody
Approved, EMA and FDA
(1998)
DLCBL, low-grade NHL or
follicular lymphoma, CLL,
RA, Wegener
granulomatosis,
microscopic polyangiitis
MS, GvHD, ITP, SLE,
PTLD, autoimmune
neuropathies or
cytopenias,
Rasmussen
encephalitis,
pemphigus vulgaris
Yes Yes B cells excluding
plasma cells and B-
cell precursors
T- and B-cell subsets
Obinutuzumab
(previously afutuzumab)
Anti-CD20 monoclonal
antibody
Approved, EMA (2014), FDA
(2013)
CLL, relapsed or refractory
or treatment-naive
follicular lymphoma
ODD for marginal
zone lymphoma
Yes Yes Same as other
CD20-targeted
agents
Potentially T- and B-cell
subsets (no long-term
data available)
Ofatumumab Anti-CD20 monoclonal
antibody
Approved, EMA (2010), FDA
(2009)
Relapsed or refractory or
recurrent CLL
No Yes (second
line in CLL)
Yes Same as other
CD20-targeted
agents
T- and B-cell subsets
Ocrelizumab Anti-CD20 monoclonal
antibody
Approved, FDA (2017), EMA
marketing authorization
(2018)
Relapsed or progressive MS NHL, RA, SLE (trial
discontinued in
2017 due to
infections)
Yes No Same as other
CD20-targeted
agents
Potentially T- and B-cell
subsets (no long-term
data available)
Veltuzumab Anti-CD20 monoclonal
antibody
Phase 1 and 2 trials in ITP,
NHL and CLL; phase 2 in
NHL; effective in refractory
NHL in association with
milatuzumab (anti-CD74)
NA ODD for CLL by
EMA and for ITP,
CLL, pemphigus
vulgaris and
superﬁcial
pemphigus by FDA
Potentially yes NA Same as other
CD20-targeted
agents
Potentially T- and B-cell
subsets (no long-term
data available)
Ublituximab Anti-CD20 monoclonal
antibody
Phase 2 terminated, phase 3
ongoing in CLL and DLBCL;
phase 2 in MS
NA ODD for DLBCL,
marginal zone
lymphoma, CLL,
NMO spectrum
disorder
Potentially yes
(ongoing trials)
NA Same as other
CD20-targeted
agents
Potentially T- and B-cell
subsets (no long-term
data available)
Ocaratuzumab Anti-CD20 monoclonal
antibody
Phase 1 and 2 trials in
haematological
malignancies; phase 3 in
pemphigus
NA No Potentially yes NA Same as other
CD20-targeted
agents
Potentially T- and B-cell
subsets (no long-term
data available)
90Y-ibritumomab tiuxetan Anti-CD20 monoclonal
antibody,
delivery of radioactive
isotope
Approved (2002) Relapsed low-grade NHL or
follicular lymphoma,
consolidation therapy in
follicular lymphoma
No Yes No Same as other
CD20-targeted
agents
T- and B-cell subsets
and granulocytes
(proximal radio-
toxicity)
Alemtuzumab (MabCampath®) Anti-CD52 monoclonal
antibody
Approved, FDA (2001), EMA
(2001, withdrawn in 2011)
CLL MS, GvHD,
conditioning
regimens
Yes No Mature
lymphocytes (not
plasma cells)
Thymocytes,
lymphocytes (not
plasma cells),
monocytes,
macrophages and
epithelial cells
Alemtuzumab (Lemtrada®) Anti-CD52 monoclonal
antibody
Approved, EMA (2013), FDA
(2014)
MS No Yes No
ALL, acute lymphoblastic leukaemia; CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B-cell lymphoma; EMA, European Medicines Agency; FDA, Food and Drug Administration; GvHD, graft versus host disease; HGG,
hypogammaglobulinaemia; ITP, immune thrombocytopenic purpura; MS, multiple sclerosis; MTX, methotrexate; NHL, non-Hodgkin's lymphoma; NMO, neuromyelitis optica; ODD, orphan drug designation; Ph, Philadelphia
chromosome; PTLD, post-transplant lymphoproliferative disorder; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, systemic sclerosis.
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Table 2
Summary of infectious events in patients treated with CD19-, CD20- and CD52-targeted agents across randomized controlled trials and observational studies that included a
control group
Agent Type of study Treatment arms No. of participants Rate of infection (novel agent versus
comparator)
Speciﬁc infections
reported in the
literature
Blinatumomab Multicentre phase 3 RCT for
ALL [6]
Blinatumomab vs standard-of-
care chemotherapy
376 (267 vs 109) Overall infection: 34% vs 52%; URTI: 7%
vs 1%; CRBSI: 6% vs 5.5%; pneumonia:
6% vs 14.7%; oral herpes: 5.6% vs 8.3%;
sepsis: 5.2% vs 7.3%; febrile
neutropenia: 24% vs 39%
IFI, CMV infection,
viral respiratory
tract infection,
enteroviral
encephalitis, PCP,
PML
Inebilizumab Multicentre phase 1 RCT for
limited or diffuse cutaneous
SS [11]
Inebilizumab vs placebo 28 Overall infection: 45.8% vs 50%
Rituximab Meta-analysis of RCTs for
malignant lymphomas [44]
17 RCTs (2 as ﬁrst-line
treatment)
5259 Overall infection: RR 1.00 (95% CI 0.87
e1.14; p 0.9); infection-related
mortality: RR 1.60 (95% CI 0.68e3.75;
p 0.3); febrile neutropenia: RR 1.14 (95%
CI 0.80e1.63; p 0.5); neutropenia: RR
1.07 (95% CI 1.02e1.12; p 0.008)
Respiratory tract
infection, fatal
reactivation of
chronic or occult
HBV, HCV or HEV
exacerbation,
enteroviral
infection, PCP, PML
Pooled safety data for
moderate to severe RA
treated with rituximab plus
methotrexate
8 RCTs, 2 long-term open-label
extension studies, 1 open-label
prospective study
3595 vs 818 placebo Overall infection rate: 75.70 (95% CI
74.31e77.11) vs 90.39 (95% CI 84.96
e96.17) per 100 patient-years
Serious infection rate: 3.76 (95% CI 3.46
e4.09) vs 3.79 (95% CI 3.49e4.12)
Ofatumumab Multicentre phase 3 RCT for
relapsed CLL [60]
Ofatumumab 474 (238 vs 236) Severe infection: 13% vs 8%
Obinutuzumab Phase 3 RCT for refractory
NHL [62]
Obinutuzumab plus
bendamustine vs
bendamustine
194 vs 202 Neutropenia: 35% vs 29%
URTI: 13% vs 9%
Sinusitis: 12% vs 5%
Phase 3 RCT as ﬁrst-line
therapy for follicular
lymphoma [63]
Obinutuzumab plus CHOP or
CVP or bendamustine vs
rituximab plus CHOP or
bedamustine
595 vs 597 Overall infection (in association with
bendamustine [338 patients per arm]):
 Induction: 8% vs 7.7%
 Maintenance: 16.7 vs 12.8%
 Follow-up: 9.3% vs 2.3%
Ocrelizumab Pooled data form 2 phase 3
RCTs for relapsing MS [65]
Ocrelizumab vs IFN-b1a 821 vs 825 URTI: 40% vs 33%; LRTI: 8% vs 5%
Phase 3 RCT for primary
progressive MS [64]
Ocrelizumab vs. placebo 732 URTI: 49% vs 43%; LRTI: 10% vs 9%; HSV:
5% vs 4%
Alemtuzumab Systematic review of RCTs
for NHL [72]
Alemtuzumab 90 mg/week for
12 weeks plus chemotherapy vs
chemotherapy
175 vs 175 CMV infection: 6% vs 0% CMV, HSV and VZV
infection, PCP
2 multicentre phase 2 to 4
RCTs for SOT recipients
[73,74]
Alemtuzumab 30 mg once vs
basiliximab 20 mg (plus long-
term tacrolimus and MMF in
both arms)
760 vs 766 Overall infection: 73% vs 75%; serious
infection: 32% vs 32%; CMV infectiona:
9.6% vs 9.5%; BKV infection: 7 vs 5%, IFI:
1% vs 1%
3 phase 2/3 RCTs for MS [75
e77]a
Alemtuzumab (12 mg/day for
5 days) vs IFN-b
1180 vs 496 Overall infection: 73% vs 58%; serious
infection: 3% vs 1%; CMV infection: 0%
vs 0%; HSV: 10% vs. 2%; VZV: 5% vs 1%
HSV, VZV, HPV
infection, TB,
listeriosis, mucosal
candidiasis (mainly
oral or vaginal)
Case series, case reports [78
e81]
NA NA PCP, invasive aspergillosis, nocardiosis,
listeriosis, PML; mycobacterial, BKV,
CMV, VZV and HSV infections; HBV
reactivation
ALL, acute lymphoblastic leukaemia; CLL, chronic lymphocytic leukaemia; CMV, cytomegalovirus; CRBSI, catheter-related bloodstream infection; HBV, hepatitis B virus; HCV,
hepatitis C virus; HEV, hepatitis E virus; HPV human papillomavirus; HSV herpes simplex virus; IFI invasive fungal infection; IFN interferon; LRTI, lower respiratory tract
infection; MMF, mycophenolate mofetil; MS, multiple sclerosis; NA, not applicable; NHL, non-Hodgkin's lymphoma; PCP, Pneumocystis jirovecii pneumonia; PML, progressive
multifocal encephalopathy; RA, rheumatoid arthritis; RCT, randomized control trial; RR, relative risk; SOT, solid organ transplantation; SS, systemic sclerosis; TB, active
tuberculosis; URTI, upper respiratory tract infection; VZV, varicella-zoster virus.
a Pooled data for trials with different alemtuzumab dose regimens.
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individuals with ALL, the rate of infection was 34% within the bli-
natumomab group compared with 52% within the conventional
chemotherapy group that mainly received FLAG regimen (ﬂudar-
abine, high-dose cytosine arabinoside and granulocyte colony-
stimulating factor with or without anthracycline), although the
occurrence of upper respiratory tract infection and intravascular
catheter-related bloodstream infection was higher among patients
receiving blinatumomab [6]. Overall, phase 2 studies withblinatumomab reported infections typically present in patients
with ALL [8,9], but higher rates of catheter-related bloodstream
infection (11% in one study and ranging from 3% to 11% for patients
aged >65 years in a second study) [9,10]. This ﬁnding could be
explained by the mode of administration of blinatumomab,
requiring continuous intravenous infusion for various numbers of
weeks.
In phase 1 and 2 trials, therapy with inebilizumab resulted in
lower serum levels of immunoglobulins [11], with no apparent
Table 3
Main characteristics of different CD20-targeted agents
Generation Drug Type Terminal half life Clinical phase
First generation: murine or chimeric
(human-mouse) antibodies
Rituximab Chimeric 18e32 days depending
on scheduling
Approved
90Y-ibritumomab Murine, conjugated with
a radioactive isotope
30 hours Approved
Second generation: humanized or fully
human antibodies developed with
the purpose of reducing
immunogenicity and improving
efﬁcacy
Ofatumumaba Fully human 14 days Approved
Ocrelizumab Humanized 26 days Approved
Veltuzumab Humanized 10e15 days Phase 2
131I-tositumomab Fully human, conjugated with
a radioactive isotope
Discontinued in 2013
Third generation: antibodies with an
engineered Fc region to boost CDC
and ADCC
Obinutuzumab Humanized 28 days Approved
Ocaratuzumab Humanized 19 days Phase 3
Ublituximab Chimeric 6 days Phase 2
ADCC, antibody-dependent cell-mediated cytotoxicity; CDC, complement-dependent cytotoxicity; Fc, crystallizable fraction.
a Induces cell lysis regardless of the level of expression of CD20, as well as rituximab-resistant CD20-positive cells.
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speciﬁc data on infection were reported in an RCT of inebilizumab
plus bendamustine versus rituximab plus bendamustine in 147
patients with relapsed or refractory CLL [13].
No clinical data on infections associated with combotox are
currently available because of the absence so far of controlled
studies [3,14].Conclusions and suggested prevention strategies
 In view of available data, which are currently limited to blina-
tumomab, therapy with CD19-targeted agents is not associated
with a meaningful increase in the risk of infection compared
with conventional chemotherapy, with overall rates comparable
to those expected in patients undergoing treatment for relapsed
or refractory ALL.
 The need for continuous 4-week intravenous infusion is prob-
ably responsible for a non-negligible rate of catheter-associated
infection among patients treated with blinatumomab. Careful
management of intravenous lines is therefore warranted to
minimize risk.
 Clinicians caring for patients receiving such therapy should be
aware of the increased risk of HGG and neutropenia, which are
associated with a well-known pattern of infectious complica-
tions. In case of severe IgG HGG, immunoglobulin replacement
therapy according to local guidelines could be considered,
particularly in case of recurrent infections.CD20-directed agents: rituximab, ofatumumab, ocrelizumab,
veltuzumab, 90Y-ibritumomab tiuxetan, 131I-tositumomab,
obinutuzumab, ocaratuzumab and ublituximab
Mechanism of action, approved indications and off-label uses
Anti-CD20 monoclonal antibodies constitute a family of tar-
geted agents mainly used in the treatment of CD20-positive B-cell
malignancies, as well as an increasing number of aggressive and/or
orphan autoimmune diseases. According to their molecular
structure, which conditions in turn the different cell-death path-
ways triggered, anti-CD20 monoclonal antibodies are divided into
three distinct generations whose main characteristics are detailed
in Table 3. At present, there are ﬁve agents approved by the FDA
and EMA for different clinical uses: rituximab (Mabthera®; Roche,
Basel, Switzerland), 90Y-ibritumomab tiuxetan (Zevalin®; Spec-
trum Pharmaceuticals, Henderson, NV), ofatumumab (Arzerra®;
Novartis Pharmaceuticals, Basel, Switzerland), obinutuzumab
(Gazyvaro® in Europe, Gazyva® in the USA, Roche) andocrelizumab (Ocrevus®, Roche). Three other agents are currently in
phase 2 (veltuzumab) or phase 3 (ocaratuzumab and ublituximab)
trials. Iodine (131I)-tositumomab (Bexxar®; GlaxoSmithKline,
Brentford, UK) was approved by FDA and received Orphan Drug
Designation by EMA in 2003, but its production and distribution
were discontinued by the manufacturer in 2014 (Table 1). Ritux-
imab was the ﬁrst anti-CD20 monoclonal antibody approved for
clinical use in 1998. It represented a cornerstone in the therapeutic
approaches to CD20-positive malignancies, and has been more
recently approved for various autoimmune conditions. It is fore-
seeable that its use will further increase due to the reduced cost of
biosimilar drugs and its well-known safety proﬁle (which allows
for risk stratiﬁcation of patients), even in combination with other
drugs.Expected impact on the infection risk
CD20 is mainly expressed on normal and malignant B cells,
beginning at the pre-B phase and progressively increasing in con-
centration until the mature stage. As neither B-cell precursors nor
plasma cells express CD20, the action of anti-CD20 monoclonal
antibodies does not immediately impair immunoglobulin produc-
tion [15]. However, HGG may subsequently occur with
increasing courses of therapy, which are generally required in
relapsingeremitting diseases. The development of HGG after CD20-
targeted therapy has been reported in patients with underlying T-
cell dysfunction, in children and in patients treated for autoimmune
diseases [16]. In particular, a clinical study including a total of 1039
patients with rheumatoid arthritis reported that serum IgM levels
fall more rapidly than either IgG or IgA levels [17]. Remarkably, in
patients with autoimmune conditions, such as systemic lupus er-
ythematosus and thrombotic thrombocytopenic purpura, the
depletion of CD20-positive B cells following rituximab adminis-
tration may induce a selective effect on autoantibody secretion,
resulting in the remission of the disease while preserving humoral
immunity [18,19].
The clinical impact in humans of HGG induced by CD20-targeted
therapy remains unclear. However, animal models suggest that the
resulting B-cell depletion may lead to a strong reduction in the
primary antibody response to neoantigens, even though memory B
and plasma cells are resistant to these agents. Recent clinical
studies highlight that after multiple courses of anti-CD20 mono-
clonal antibodies, individuals with autoimmune diseases may
develop a clinical condition similar to common variable immuno-
deﬁciency, with the degree of HGG being directly associated with
infection rates, although severe infections are generally infrequent
[20]. Severe long-lasting HGG has also been reported [21].
Table 4
Summary of risk of infectious complications and possible management strategies for the reviewed targeted agents
Group Agent Risk of
neutropenia
Risk of HSV and VZV
(anti-herpesvirus
prophylaxis warranted)
Risk of PCP (anti-Pneumocystis
prophylaxis warranted)
Risk of HBV reactivation
(prophylaxis warranted for
HBsAgþ/HBsAge anti-HBcþ)
Risk of CMV infection
(monitoring warranted)
Other infections to be
considered
CD19-targeted
agents
Blinatumomab No Yes Yes Yes/yes ND Immunoglobulin
replacement therapy if
severe HGG
Inebilizumab ND ND (probably in
haematological
malignancies)
ND Probably yes/yes ND Immunoglobulin
replacement therapy if
severe HGG
CD20-targeted
agents
Rituximab Yes ND (consider in
haematological
malignancies depending
and concomitant therapy)
Possible (consider if
concomitant corticosteroid
therapy)
Yes/yes ND, symptom-based
approach in haematological
malignancies
PML, HCV, enteroviral
infections
Obinutuzumab Potentially yes ND (consider depending on
underlying disease and
concomitant therapy)
ND, consider depending on
underlying disease and
concomitant therapy
ND, probably yes/yes ND, symptom-based
approach in haematological
malignancies
Enteroviral infections
Ofatumumab Yes ND (consider depending on
underlying disease and
concomitant therapy)
ND, consider depending on
underlying disease and
concomitant therapy
Yes/yes ND, symptom-based
approach in haematological
malignancies
Veltuzumab Potentially yes ND (consider if
haematological
malignancies depending
and concomitant therapy)
ND, possibly as rituximab ND, probably yes/yes ND, symptom-based
approach in haematological
malignancies
Ocrelizumab Potentially yes No ND (consider depending on
underlying disease or
concomitant therapies)
ND, probably yes/yes No PML (consider based on
data with rituximab and
previous treatment with
natalizumab)
CD52-targeted
agents
Alemtuzumab
(MabCampath®)
Yes Yes Yes Yes/prophylaxis or
monitoring
Yes IFI, BK and JC
polyomaviruses
reactivation
Alemtuzumab (Lemtrada®) No Yes No (lower dose, no need of
additional
immunosuppression)
Probably
yes/prophylaxis or
monitoring
No HPV, TB, listeriosis,
candidiasis
CMV, cytomegalovirus; HBc, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HPV, human papillomavirus; HSV, herpes simplex virus; IFI, invasive fungal infection; ND,
no data available; PCP, Pneumocystis jirovecii pneumonia; PML, progressive multifocal encephalopathy; TB, active tuberculosis; VZV, varicella-zoster virus.
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Fig. 1. Mode of action of blinatumomab, a ﬁrst-in-class bispeciﬁc T-cell engager (BiTE) engineered using a diabody approach. This agent results from combining two variable regions
(VH and VL) of normal antibodies with different speciﬁcities. One of these region binds to CD3 on the surface of cytotoxic T cells, while the other binds to CD19, which is largely
expressed on the majority of B precursor acute lymphoblastic leukaemia blasts. The elimination of the constant regions of these antibodies allows for close approximation of both
cells, thereby facilitating T-cell-mediated killing of the bound malignant B cells.
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modulating B-/T-cell interactions rather than directly affecting
humoral immunity. In addition to antibody production, B cells play
a pivotal role in activating T cells through antigen presentation and
cytokine release. A signiﬁcant amount of evidence suggests that B-
cell depletion exerts a deleterious impact on the induction, main-
tenance and activation of cell-mediated immunity [22], and in vivo
studies suggest that rituximab therapy induces a decrease in in-
ﬂammatory cytokines among patients with autoimmune disorders
[23]. Moreover, there are post-marketing reports of patients treated
with anti-CD20 monoclonal antibodies who strongly associated
with impaired cellular immunity [24], such as progressive multi-
focal leucoencephalopathy [25], Pneumocystis jirovecii pneumonia
(PCP) [26], hepatitis C virus (HCV) reactivation [27] and dissemi-
nated varicella-zoster virus (VZV) infection [24,28,29]. Dissemi-
nated and/or severe enteroviral infections, probably associated
with HGG, have also been reported [30e32].
A recent animal model study proved that B cells do not affect
secondary T-cell responses against viral pathogens (i.e. once
memory T cells are already established). However, B-cell depletion
before or during primary viral infection signiﬁcantly impairs
cytokine production and generation of new memory CD4þ T cells,
thus increasing the risk of systemic primary infections [33].
In addition to the B-cell-dependent mechanism, CD20-targeted
agents can directly affect cell-mediated immunity by targeting T
cells. In particular, rituximab has been used for treating graft
rejection after kidney transplantation and graft-versus-host disease
following allogenic haematopoietic stem cell transplantation.
Moreover, it has been recently discovered that about 3%e5% of
human T cells express CD20 (CD3þ CD20þ T cells). These cells are
widely represented in primary and secondary lymphatic tissues,
blood and central nervous system, and are selectively depleted by
CD20-targeted agents. The natural function of this T-cell subset is
currently unclear. However, their depletion seems to have a central
role in the remission of multiple sclerosis in patients treated with
anti-CD20 monoclonal antibodies [34].
The effect of this therapy on non-lymphoid immune cells should
also be kept in mind. Severe (grade 3e4) neutropenia is reported in
10%e33% of patients receiving any of the four approved non-
conjugated anti-CD20 monoclonal antibodies. Although concomi-
tant use of chemotherapy may have a role, post-marketing studies
report that severe neutropenia is also possible in patients who
receive such agents as sole therapy [35]. The occurrence ofneutropenia with conjugated antibodies such as 90Y-ibritumomab is
muchmore frequent (with rates exceeding50%) and severe thanwith
non-conjugated compounds, inwhich early neutropenia is rare [36].
A peculiar condition associated with the use of anti-CD20
monoclonal antibodies is the so-called late-onset neutropenia.
This entity has been largely described with rituximab [35],
although preliminary studies do suggest that similar conditions
might be associated with ofatumumab [37] and obinutuzumab
[38]. In overall terms, late-onset neutropenia occurs between 1 and
5 months after the end of therapy in 5%e15% of patients treated
with rituximab. It can persist for months and eventually resolve
spontaneously, yet in some cases it evolves to have a persistent
course with poor or transient response to granulocyte colony-
stimulating factor therapy [39]. The mechanism of late-onset
neutropenia is probably immune-mediated, and its impact on the
risk of infections is unclear.
The effect of CD20-targeted therapy on vaccination has been
reviewed elsewhere [40,41]. Impaired responses has been reported
for inﬂuenza, Streptococcus pneumoniae polysaccharide and Hae-
mophilus inﬂuenzae type b (Hib) conjugate vaccines, although a
recent prospective study demonstrated that pneumococcal and Hib
vaccines administered at least after 6 months from the rituximab
infusion have high efﬁcacy in preventing mild and severe respira-
tory infections in patients with immune thrombocytopenia [42].
The response to inﬂuenza vaccine was universally absent within
6 months from the last rituximab administration in patients with
haematological malignancies [43].
Available clinical data
Meta-analysis and pooled data analysis of rituximab in patients
with lymphoma [44] and rheumatoid arthritis [45] did not show an
increase in the incidence of infections compared with placebo
(Table 2). However, a large population study in patients with im-
mune thrombocytopenia showed that the risk of serious infections
(both viral and bacterial) was 2.6 times higher in participants who
received rituximab compared with those who did not, whereas
such increase for corticosteroids was estimated as 3.8 times [42].
It should be emphasized that the studies included in the meta-
analyses did not speciﬁcally evaluate the occurrence of most
frequent infectious complications, but the role of rituximab in the
reactivation of both chronic and apparently resolved hepatitis B
virus (HBV) infection has been extensively documented [46e48],
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immunosuppressive therapy without rituximab [46], and 109 fatal
cases documented in the Adverse Even reporting System [49]. For
example, the rate of HBV reactivation among hepatitis B surface
antigen (HBsAg)-negative/anti-hepatitis B core antibody (HBc)-
positive lymphoma patients treated with rituximab-containing
regimens (R-CHOPdrituximab, cyclophosphamide, doxorubicin,
vincristine and prednisone) was 24% compared with no cases in
those treated with chemotherapy without rituximab [50]. Antiviral
prophylaxis was effective in reducing the reactivation risk and is
currently recommended by various guidelines [51,52]. Antiviral
prophylaxis should be offered both to HBsAg-positive and HBsAg-
negative/anti-HBc-positive patients for at least 12e18 months af-
ter the last administration of anti-CD20 agent because delayed
cases of HBV reactivation have been reported [53]. Monitoring for
HBV reactivation should be performed for at least 12 months after
the end of antiviral prophylaxis.
Lamivudine has been the most frequently used antiviral agent in
this setting. Few studies on direct head-to-head comparison be-
tween lamivudine and drugs with higher genetic barrier to HBV
resistance have been performed, and the beneﬁt of the latter has
been reported in HBsAg-positive lymphoma patients [50]. Never-
theless, several guidelines recommend potent antivirals, such as
entecavir or tenofovir, for prophylaxis in HBsAg-positive patients
receiving anti-CD20 therapy [51e53]. For HBsAg-negative/anti-HBc-
positive patients, antiviral prophylaxis could be replaced by frequent
(usually monthly) HBV-DNA monitoring and pre-emptive antiviral
treatment in case of a positive result, but such a strategy might be
more expensive andprone to poor compliance thanprophylaxis [50].
Additionally, exacerbation of HCV, chronic hepatitis E virus
infection and severe enterovirus infections have been reported in
patients receiving rituximab therapy [30e32,54,55], as have
opportunistic infections resulting from impaired cell-mediated
immunity such as progressive multifocal leucoencephalopathy or
P. jirovecii pneumonia. A meta-analysis of 11 cohort studies
suggested that the use of rituximab-containing regimens in pa-
tients with lymphomawas associated with a signiﬁcantly increased
risk for P. jirovecii pneumonia, (with a risk ratio of 3.65). However,
the incidence rate among the 942 rituximab-exposed patients was
relatively low (2.97%). This risk was inversely associated with the
receipt of anti-Pneumocystis prophylaxis [56]. However, a more
recent single-centre study including 689 patients with B-cell
lymphoma treated with R-CHOP concluded that the cumulative
incidence of PCP until 180 days after the last cycle of therapy was
low (1.5%) and below the conventional threshold for considering
the use of prophylaxis [57]. Additionally, the risk of PCP has been
reported to be higher among lymphoma patients receiving R-CHOP
chemotherapy every 14 days compared with 21-day regimens [26].
Indeed, recent guidelines consider anti-Pneumocystis prophylaxis
as optional only for R-CHOP-14 but not for R-CHOP-21, whereas the
use of rituximab itself is not considered an indication [58]. Of note,
prophylaxis should be provided to all the patients receiving
steroids at the dose of 20 mg of prednisone daily (or equivalent) for
at least 4 weeks [58].
Several biosimilars of rituximab are currently available. Direct
comparison regarding the incidence and nature of infectious
complications between rituximab and these biosimilars is lacking,
but meta-analyses report similar efﬁcacy and safety [59].
The higher rate of toxicity observed with 90Y-ibritumomab
tiuxetan thanwith rituximab is mainly due to the effect of radiation
on cells surrounding the CD20-positive targets, causing severe
leucopenia. Nevertheless, the spectrum of infections is similar to
rituximab.
There are few data available for ofatumumab, but the rates re-
ported for overall and severe infection ranged from 33% to 53% and1% to 5%, respectively. Notably, no cases of active tuberculosis have
been reported, even among patients coming from high-prevalence
countries. A single case of fulminant HBV infection was reported in
awoman concomitantly treatedwithmethotrexate. A pivotal phase
3 open label trial assessing the efﬁcacy and safety of ofatumumab
as sole maintenance agent versus observation in 477 patients with
CLL showed that progression-free survival was improved in those
allocated to the ofatumumab arm. However, infections (respiratory
tract and herpes simplex virus) and neutropenia were also more
common in the ofatumumab group than in the control group [60].
In pivotal trials of obinutuzumab in combination with chlor-
ambucil for CLL, severe and life-threatening cytopenias were
frequent, both neutropenia (40% overall; 34% for grade 3e4) and
thrombocytopenia (15% overall, 11% for grade 3e4) [61]. Similar to
that reported with rituximab, cases of disseminated enterovirus
infection have been described in patients treated with obinutuzu-
mab [31,32]. Adding obinutuzumab to bendamustine in 396 pa-
tients with indolent Hodgkin's lymphoma who had failed
rituximab, resulted in higher rates of neutropenia and upper res-
piratory tract infection compared with bendamustine mono-
therapy [62]. Finally, in an RCT with rituximab as comparator, the
rate of infectious complications was higher in the obinutuzumab
arm, particularly when used in association with bendamustine
during maintenance and follow-up phases [63].
In phase 3 RCTs, ocrelizumab showed better efﬁcacy than
interferon-b or placebo in the treatment of primary progressive or
relapsing multiple sclerosis, respectively [64,65]. Infection rates
were overall high, exceeding 50% for both ocrelizumab and control
arms, although severe infections were uncommon. Upper respira-
tory tract infection and oral herpes occurred more frequently
among patients receiving ocrelizumab. On the other hand, ocreli-
zumabwasmarginally safer than interferon-bwith regard to severe
infections (1.3% versus 2.9%, respectively) [65]. Ocrelizumab ther-
apy seems to be less safe when used in combination with other
immunosuppressive agents. Clinical development of ocrelizumab
as combination therapy for rheumatoid arthritis [66] and prolifer-
ative lupus nephritis [67] was terminated by the sponsor due to an
increased incidence of serious infections.
Optimizing vaccine status may contribute to reduce the risk of
severe infections among patients treated with anti-CD20 mono-
clonal antibodies. Non-live vaccines are safe and efﬁcacious, espe-
cially if administered 4 weeks before treatment. Efﬁcacy of non-live
vaccination during or immediately after CD20-targeted therapy is
more debated, and experimental and clinical data show that sero-
conversion is absent or severely impaired during at least 6 months
after administration of rituximab [43,68]. However, population
studies suggested that vaccination may improve both quality and
expectancy of life, and clinical trials to optimize the vaccine scheme
in patients receiving CD20-targeted therapies are ongoing. As there
is no evidence on safety or efﬁcacy of live vaccines in patients who
undergo anti-CD20 therapy, they should not be administered.
Finally, it should be noted that the use of anti-CD20 monoclonal
antibodies for chronic conditions (i.e. autoimmune diseases and
indolent lymphomas) is increasing and, therefore, there is a need to
establish best strategies for the management of late-onset com-
plications among patients receiving multiple courses of treatment.
As many of these patients might be not eligible for standard RCTs,
large population and open-label extension studies or adaptive trials
may help to deﬁne such preventive approaches.
Conclusions and suggested prevention strategies
 In view of available data, therapy with CD20-targeted agents (in
particular the newer anti-CD20 monoclonal antibodies) is
associated with at least a moderate increase in the risk of
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haematological adverse effects of anti-CD20 monoclonal anti-
bodies (including severe respiratory tract infection and HBV
reactivation and, to a lesser extent, HCV reactivation and VZV
infection).
 The increased risk of infection associated with the use of sec-
ond- and third-generation anti-CD20 monoclonal antibodies
should be individually evaluated in the light of patient's co-
morbidities and the concomitant administration of other
immunosuppressive agents (in particular, this latter factor may
render unacceptably high the risk of severe infections).
 There are few data on the clinical impact of cytopenias associ-
ated with the newest anti-CD20 monoclonal antibodies (such as
ocrelizumab or obinutuzumab).
 Current evidence suggests that the addition of rituximab to
conventional chemotherapy is not associated with an increased
risk of PCP compared with chemotherapy alone, so anti-Pneu-
mocystis prophylaxis in patients treated with rituximab should
be considered only in those also receiving concomitant thera-
pies which are themselves associated with an increased risk of
PCP, including corticosteroids (prednisone 20 mg daily or
equivalent dose for at least 4 weeks) [58].
 Screening for chronic or resolved HBV infection should be per-
formed before starting treatment with CD20-targeted agents.
 Antiviral prophylaxis while on anti-CD20 therapy and for at
least 12e18 months after the last dose should be administered
to HBsAg-positive patients for preventing HBV reactivation.
Antiviral agents with high genetic barrier to HBV resistance (e.g.
entecavir) should be used. Monitoring for HBV reactivation
should be performed for at least 12 months after the end of
antiviral prophylaxis.
 Prophylaxis (usually with lamivudine) should be offered to
HBsAg-negative/anti-HBc-positive patients to prevent the
reactivation of resolved HBV infection [69].
 Age-appropriate inactivated vaccinations (e.g. inﬂuenza, pneu-
mococcal and Hib) should be provided according to current
guidelines [70]. There are no data on the safety and efﬁcacy of
live-virus vaccines (i.e. VZV or measles-mumps-rubella) in pa-
tients receiving anti-CD20 monoclonal antibodies. Therefore,
such vaccines should not be provided until at least 6 months
after completion of CD20-targeted therapy.
CD52-targeted agents: alemtuzumab
Mechanism of action, approved indications and off-label uses
Alemtuzumab (MabCampath® or Lemtrada®; Genzyme-Sanoﬁ,
Cambridge, MA, USA) is a humanized IgG1 monoclonal antibody
that binds to CD52 and leads to the lysis of targeted cells by
means of complement-dependent cytotoxicity and/or antibody-
dependent cell-mediated cytotoxicity. In May 2001 it was
approved by the FDA for the treatment of B-cell CLL in patients who
have been treated with alkylating agents and have failed on ﬂu-
darabine therapy. This indication is not currently supported by the
EMA. In 2013 alemtuzumab was EMA-approved, at a signiﬁcantly
lower dose, for the treatment of multiple sclerosis. In addition, off-
label uses of alemtuzumab includes the treatment of Hodgkin's and
non-Hodgkin's lymphomas, prevention (as induction therapy) or
treatment of graft rejection in solid organ transplantation, and
prevention or treatment of graft-versus-host disease after allogenic
haematopoietic stem cell transplantation (Table 1).
The standard dose of alemtuzumab for patients with B-cell CLL
is 30 mg three times weekly for up to 12 weeks (maximum dose
1080 mg per year), whereas for multiple sclerosis a two-cycle
regimen of 12 mg daily for 5 days (total dose 60 mg), followed12 months later by 12 mg daily for 3 days (total dose 36 mg) is
recommended.
Expected impact on the infection risk
CD52 is expressed onmost mature lymphocytes (but not plasma
cells), monocytes, macrophages, epithelial cells and thymocytes.
Alemtuzumab induces severe depletion of peripheral blood lym-
phocytes (both T and B cells, especially CD4þ), and this effect is
more profound and long-lasting with repeated infusions. In view of
the notable impact on the CD4þ T-cell subset, the expected infec-
tion risk is similar to the spectrum observed in advanced human
immunodeﬁciency virus infection, with increased incidence of
classic opportunistic infections (e.g. herpesvirus infections, PCP or
mycobacterial infections). Even with the lower doses of alemtu-
zumab used in multiple sclerosis, decreased CD4þ T-cell counts
(<200 cells/mL) have been reported to persist months after the
completion of therapy [71].
Available clinical data
Alemtuzumab has been tested in numerous phase 3 RCTs for B-
cell CLL, induction therapy in kidney transplant recipients and
multiple sclerosis. Additionally, there have been phase 2 trials in
rheumatoid arthritis and other conditions. Infectious complications
have been reported in the setting of these phase 3 trials, as well as
in a number of smaller studies, case series and case reports. The
highest rates were found in patients with B-cell CLL and kidney
transplant recipients, whereas the lowest were in multiple sclerosis
[72e81]. Different dosing regimens, disease-related immunosup-
pression, and the prior or concomitant use of other agents most
likely account for these differences (Table 2).
The risk of cytomegalovirus (CMV) infection was increased in
non-Hodgkin's lymphoma trials, whereas herpes simplex virus and
VZV were more commonly found in multiple sclerosis studies. The
incidence of CMV infection was lower than one episode per 100
patient-years in pivotal multiple sclerosis trials. Anti-herpesvirus
prophylaxis was the standard of care for participants in RCTs for
haematological malignancies, and it was also recommended after
the results of the pivotal studies in multiple sclerosis. Due to the
perceived risk of PCP, standard anti-Pneumocystis prophylaxis has
been advocated early as standard treatment. There have been case
reports of HBV and HCV reactivation in patients with haemato-
logical malignancies treated with alemtuzumab. As such patients
were excluded from trials in multiple sclerosis, the risk of these
complications remains to be established for this particular popu-
lation. Finally, a higher rate of human papillomavirus infection (2%),
and single cases of listeriosis and tuberculosis have been reported
in pivotal trials in multiple sclerosis. Therefore, annual human
papillomavirus screening is recommended for female patients ac-
cording to the FDA- and EMA-approved package insert of
Lemtrada®.
Conclusions and suggested prevention strategies
 In view of available data, therapy with CD52-targeted agents
(alemtuzumab) is associated with a major increase in the risk of
infection, with a spectrum of syndromes and causative agents
typical for severe quantitative T-cell defects (i.e. similar to
advanced human immunodeﬁciency virus infection). This risk is
clearly dependent on the dose regimen used (which depends in
turn on the underlying indication), additional immunosup-
pressive therapies and prophylactic strategies applied.
 Anti-Pneumocystis prophylaxis should be administered to pa-
tients receiving alemtuzumab for haematological malignancies,
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throughout the entire course of therapy. The duration of pro-
phylaxis upon discontinuation of alemtuzumab therapy is not
well established, although it seems reasonable to continue its
administration for at least 2e6 months or, alternatively, until
the peripheral blood CD4þ T-cell count recovers to 200 cells/
mL.
 Prevention strategies for CMV infection (antiviral prophylaxis or
pre-emptive therapy guided by CMV-DNA detection or
symptom-based approach) should be applied to CMV-
seropositive patients receiving alemtuzumab for haemato-
logical malignancies, solid organ transplantation and other off-
label indications. The election of any of these strategies may
be additionally inﬂuenced by other factors (e.g. donor/recipient
serostatus in solid organ transplantation and haematopoietic
stem cell transplantation).
 Anti-herpesvirus (i.e. herpes simplex virus or VZV) prophylaxis
should be administered to patients receiving alemtuzumab for
haematological malignancies, solid organ transplantation and
other off-label indications. Patients treated for multiple sclerosis
should receive anti-herpesvirus prophylaxis from the ﬁrst day of
each treatment cycle and continue for at least 2 months or,
alternatively, until the peripheral blood CD4þ T-cell count re-
covers to 200 cells/mL.
 Screening for chronic or resolved HBV and for chronic HCV
infection should be performed before starting treatment with
alemtuzumab. Antiviral prophylaxis while on therapy and for at
least 6e12 months after the last dose should be administered to
HBsAg-positive patients for preventing HBV reactivation. In
addition, prophylaxis with lamivudine (or, alternatively, close
monitoring for HBV viral load followed by pre-emptive antiviral
treatment) should be administered to HBsAg-negative/anti-
HBc-positive patients to prevent the eventual reactivation of
occult HBV infection [69].
 Screening for latent tuberculosis infection should be performed
before starting alemtuzumab therapy, followed by appropriate
therapy if needed.
 Annual human papillomavirus screening is recommended for
female patients receiving alemtuzumab.
 Counselling on appropriate hygienic and food safety measures
that might reduce the risk of listeriosis (e.g. to avoid unpas-
teurized milk and its products, certain soft cheeses like brie or
feta, raw or undercooked meat) or toxoplasmosis among Toxo-
plasma-seronegative patients (e.g. avoid raw or undercooked
meat and contact with cat faeces) should also be provided.
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